Foghorn Therapeutics (FHTX) Retained Earnings (2019 - 2026)

Foghorn Therapeutics' Retained Earnings history runs 8 years deep, the most recent figure standing at -$652.3 million for Q1 2026.

• In Q1 2026, Retained Earnings fell 13.05% year-over-year to -$652.3 million; the TTM figure through Mar 2026 stood at -$652.3 million (down 13.05% YoY), while the FY2025 annual figure was -$632.5 million, down 13.31% from the prior year.
• Retained Earnings was -$652.3 million for Q1 2026 at Foghorn Therapeutics, down from -$632.5 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$1.2 million in Q1 2022 to a low of -$652.3 million in Q1 2026.
• Historically, Retained Earnings has averaged -$379.0 million across 5 years, with a median of -$496.6 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Retained Earnings surged 99.45% in 2023, then plunged 28357.47% in 2024.
• A 5-year view of Retained Earnings shows it stood at -$4.0 million in 2022, then slumped by 11730.51% to -$471.6 million in 2023, then dropped by 18.37% to -$558.2 million in 2024, then decreased by 13.31% to -$632.5 million in 2025, then retreated by 3.14% to -$652.3 million in 2026.
• The last three Retained Earnings figures came in at -$652.3 million (Q1 2026), -$632.5 million (Q4 2025), and -$610.8 million (Q3 2025), per Business Quant data.